Neurocrine reports Q3 adjusted EPS $2.17, consensus $2.07

Reports Q3 revenue $794.9M, consensus $747.22M. “Neurocrine’s (NBIX) third quarter commercial results highlight the meaningful impact that INGREZZA and CRENESSITY are having on patients’ lives. INGREZZA achieved another record quarter in new patient starts and total prescriptions, further demonstrating continued unmet need within the tardive dyskinesia and Huntington’s chorea market. CRENESSITY’s strong launch reflects its status as a first-in-class therapy that is changing standard of care treatment for patients with classic congenital adrenal hyperplasia,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “With registration-enabling clinical trials enrolling for osavampator in major depressive disorder and direclidine in schizophrenia, Neurocrine Biosciences is well positioned to lead the next wave of innovation in neuroscience, advancing transformative therapies that meaningfully improve the lives of patients.”